Protagenic Therapeutics (NASDAQ:PTIX) is trading down 6.6%

Protagenic Therapeutics, Inc. (NASDAQ:PTIX – Get a Free Report) fell 6.6% during trading on Monday. The stock traded as low as $1.52 and last traded at $1.56. About 35,200 shares traded during trading, an increase of 182% from the average daily volume of 12,502 shares. The stock previously closed at $1.67.

Protagenic therapies Price-performance

The company has a 50-day moving average of $1.48 and a 200-day moving average of $1.11. The stock has a market cap of $6.93 million, a price-to-earnings ratio of -1.36 and a beta of 0.44.

Protagenic Therapeutics (NASDAQ:PTIX – Get Free Report) posted its latest quarterly results on Monday, April 1. The company reported ($0.38) earnings per share for the quarter.

Protagenic Therapeutics Company Profile

(Get a free report)

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapies for the treatment of stress-related neuropsychiatric disorders and mood disorders. The company’s lead product consists of PT00114, a synthetic form of teneurin carboxy terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.

read more

Receive daily news and reviews for protagenic therapies – Enter your email address below to receive a daily digest of the latest news and analyst ratings for Protagenic Therapeutics and related companies with’s FREE daily email newsletter.

Back To Top